Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(118 productos)
- EGFR(586 productos)
- FAK(72 productos)
- FLT(89 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(180 productos)
- JAK(245 productos)
- PDGFR(129 productos)
- RAAS(88 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(54 productos)
- VDA(2 productos)
- VEGFR(245 productos)
Mostrar 6 subcategorías más
Se han encontrado 2275 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.Fórmula:C25H18N4O3Pureza:98%Forma y color:SolidPeso molecular:422.44MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Fórmula:C25H29ClN8O2Forma y color:SolidPeso molecular:509Syk-IN-4
Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.Forma y color:SolidAD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Fórmula:C22H21ClF3N7OPureza:98%Forma y color:SolidPeso molecular:491.9JAK1/TYK2-IN-1
CAS:JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).Fórmula:C18H20F3N7OForma y color:SolidPeso molecular:407.401BMS-599626 2HCL(714971-09-2 Free base)
CAS:BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.Fórmula:C27H29Cl2FN8O3Pureza:99.11%Forma y color:Odour SolidPeso molecular:603.47EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Fórmula:C24H16N6OS2Pureza:98%Forma y color:SolidPeso molecular:468.55SIAIS178
CAS:SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Fórmula:C50H62ClN11O6S2Pureza:98.07%Forma y color:SolidPeso molecular:1012.68Ref: TM-T12907
1mg160,00€5mg376,00€10mg512,00€25mg938,00€50mg1.510,00€100mg2.167,00€200mg2.822,00€1mL*10mM (DMSO)414,00€PTD10
CAS:PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.Fórmula:C49H51N11O8Pureza:99.12%Forma y color:SolidPeso molecular:922Src Inhibitor 4
Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.Fórmula:C33H34N4O3Forma y color:SolidPeso molecular:534.648EGFR-IN-22
CAS:EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).Fórmula:C38H47BrFN10O2PForma y color:SolidPeso molecular:805.72dALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Fórmula:C39H45ClN7O5PForma y color:SolidPeso molecular:758.245SNIPER(ABL)-050
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.Fórmula:C68H84N12O9Pureza:98%Forma y color:SolidPeso molecular:1213.47EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Fórmula:C49H32N12O2S2Pureza:98%Forma y color:SolidPeso molecular:884.99Angiogenesis related Compound Library
A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and highForma y color:Odour SolidRef: TM-L4800
1mgA consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarMulti-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPureza:98%Forma y color:Odour SolidKIT/PDGFRA-IN-1
KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.
Fórmula:C26H18F3N5O2Forma y color:SolidPeso molecular:489.449TL13-110
CAS:Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Fórmula:C49H62ClN9O9SForma y color:SolidPeso molecular:988.59PROTAC EGFR degrader 7
Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.Fórmula:C46H48N10O6Forma y color:SolidPeso molecular:836.94VSLRGDTRG
CAS:VSLRGDTRG is a synthetic peptide derived from the RGD motif in cadherin17 (CDH17) that binds to the α2β1 integrin, activating its signaling pathways. By promoting high-affinity conformational changes in β1 integrins through the RGD motif, VSLRGDTRG enhances cell adhesion and the phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. This peptide is useful for research on cancers expressing CDH17, such as colorectal and pancreatic cancer.Fórmula:C38H69N15O14Forma y color:SolidPeso molecular:960.047Scr-IN-1
Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.Fórmula:C26H16ClF3N2O3Forma y color:SolidPeso molecular:496.87Sozinibercept
CAS:Sozinibercept (OPT 302; VGX-300), a VEGFR-3 inhibitor, blocks VEGF-C/D to curb angiogenesis and vascular leakage, and treats rat diabetic retinal edema.Forma y color:LiquidHIF-1 inhibitor-4
CAS:HIF-1 inhibitor-4 (HIF-1 inhibitor-4) is a HIF-1 inhibitor with IC50 of 560 nM.Fórmula:C18H19IN2O2Pureza:99.26%Forma y color:SolidPeso molecular:422.26TL13-12
CAS:TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).Fórmula:C45H53ClN10O10SPureza:98%Forma y color:SolidPeso molecular:961.49AG-1478 hydrochloride
CAS:AG1478 HCl is an epidermal growth factor receptor protein inhibitor.Fórmula:C16H15Cl2N3O2Forma y color:SolidPeso molecular:352.21INCB-000928
CAS:Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.
Fórmula:C30H38N4O3Pureza:98.93%Forma y color:SolidPeso molecular:502.65Sorafenib-d4
CAS:Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.Fórmula:C21H16ClF3N4O3Pureza:98%Forma y color:SolidPeso molecular:468.85cep-5214
CAS:CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.Fórmula:C28H28N2O3Forma y color:SolidPeso molecular:440.53HIF-1 Signaling Pathway Compound Library
A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；Forma y color:Odour SolidRef: TM-L8500
1mgA consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarDD0-2363
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.Fórmula:C36H36ClFN6O4Forma y color:SolidPeso molecular:671.16Timigutuzumab
CAS:Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].Forma y color:LiquidEGFR/HER2/DHFR-IN-3
EGFR/HER2/DHFR-IN-3 (compound 4c) serves as an efficacious dual inhibitor specifically targeting EGFR/HER2, exhibiting IC50 values of 0.138 μM for EGFR and 0.Pureza:98%Forma y color:Odour SolidPROTAC EGFR degrader 4
CAS:PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).Fórmula:C55H70N12O4SForma y color:SolidPeso molecular:995.29ALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Fórmula:C24H30ClN6O2PForma y color:SolidPeso molecular:500.97Efruxifermin
CAS:Efruxifermin, a modified FGF21 with IgG1 Fc, has increased stability and affinity. Used in non-alcoholic steatohepatitis research.Forma y color:LiquidDB1113
CAS:DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.Fórmula:C59H68F3N13O6SForma y color:SolidPeso molecular:1144.31SNIPER(ABL)-033
CAS:SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL proteinFórmula:C61H73F3N10O9S2Pureza:98%Forma y color:SolidPeso molecular:1211.42LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Fórmula:C29H31F3N6O2SForma y color:SolidPeso molecular:584.66ALK-IN-9
CAS:ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.Fórmula:C20H21FN6O3Forma y color:SolidPeso molecular:412.425Secretin, canine
CAS:Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.Fórmula:C131H222N44O41Pureza:98%Forma y color:SolidPeso molecular:3069.43Verucopeptin
CAS:Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.Fórmula:C43H73N7O13Forma y color:SolidPeso molecular:896.08BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Fórmula:C23H32N4O5Forma y color:SolidPeso molecular:444.532Simotinib hydrochloride
CAS:Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.Fórmula:C25H27Cl2FN4O4Forma y color:SolidPeso molecular:537.41DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Forma y color:LiquidPF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Fórmula:C46H50F3N13O8Pureza:98%Forma y color:SolidPeso molecular:969.97TYK2 activator-1
TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.Fórmula:C23H21FN4O2Forma y color:SolidPeso molecular:404.16485VEGFR-2-IN-64
VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.Fórmula:C72H123N9O6Forma y color:SolidPeso molecular:1210.8SI-2
CAS:SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.Fórmula:C15H15N5Pureza:98.4%Forma y color:SolidPeso molecular:265.31Ref: TM-T28773
1mg378,00€5mg922,00€10mg1.225,00€25mg1.853,00€50mg2.490,00€100mg3.353,00€1mL*10mM (DMSO)845,00€SNIPER(ABL)-015
SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5Fórmula:C58H70F3N9O9Pureza:98%Forma y color:SolidPeso molecular:1094.237-Hydroxyneolamellarin A
CAS:7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.Fórmula:C24H19NO5Forma y color:SolidPeso molecular:401.41Varlitinib
CAS:Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.Fórmula:C22H19ClN6O2SPureza:99.7%Forma y color:SolidPeso molecular:466.94HER2/neu (654-662) GP2
CAS:Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.Fórmula:C42H77N9O11Pureza:98%Forma y color:SolidPeso molecular:884.112-Keto Crizotinib
CAS:2-Keto Crizotinib is an active lactam metabolite of crizotinib.Fórmula:C21H20Cl2FN5O2Pureza:98%Forma y color:SolidPeso molecular:464.32JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Fórmula:C28H38N6O5SPureza:98%Forma y color:SolidPeso molecular:570.7Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Pureza:98%Forma y color:Odour SolidEGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Fórmula:C22H16N4OSForma y color:SolidPeso molecular:384.45EGFR-IN-162
EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.Fórmula:C27H31N3O2Forma y color:SolidPeso molecular:429.24163EGFR-IN-151
EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.Forma y color:Odour SolidMS9427
CAS:MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.Fórmula:C48H58ClFN8O12Forma y color:SolidPeso molecular:993.47Cetuximab (PBS)
Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.Forma y color:Odour LiquidALK-IN-13
CAS:ALK-IN-13 is an ALK inhibitor.
Fórmula:C29H39ClN7O2PForma y color:SolidPeso molecular:584.1OK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Fórmula:C42H62N14O9Pureza:98%Forma y color:SolidPeso molecular:907.03MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Fórmula:C26H23N7OPureza:98%Forma y color:SolidPeso molecular:449.51Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77Si5-N14
CAS:Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.Fórmula:C78H160N6O5Si2Forma y color:SolidPeso molecular:1318.31HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Forma y color:Odour SolidPulocimab
CAS:Pulocimab, an anti-VEGFR2 monoclonal antibody (mAb), is utilized in cancer research [1].Forma y color:LiquidFW-1
FW-1 is a type I inhibitor of FLT3, with an IC50 of approximately 1 μM. It exhibits cytotoxic effects in FLT3-mutant AML cells, causes cell cycle arrest at the G0/G1 phase, and induces apoptosis in MV4-11 and MOLM-13 cells.
Fórmula:C24H27N7OForma y color:SolidPeso molecular:429.517EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Fórmula:C17H15N7O5SForma y color:SolidPeso molecular:429.41DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Fórmula:C55H62N10O8Forma y color:SolidPeso molecular:991.163PF15
CAS:PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Fórmula:C44H49N13O6Pureza:98%Forma y color:SolidPeso molecular:855.94BW710
BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.
Fórmula:C28H29FN6O2SForma y color:SolidPeso molecular:532.63Duligotuzumab
CAS:Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.Pureza:97.7% (SDS-PAGE); 96.3% (SEC-HPLC) - ≥95% (SDS-PAGE); 95.19% (SEC-HPLC)Forma y color:LiquidMS9449
CAS:MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Fórmula:C60H76ClFN10O8SPureza:98%Forma y color:SolidPeso molecular:1151.82PROTAC BTK Degrader-6
CAS:PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expressionFórmula:C45H47N11O6Pureza:98%Forma y color:SolidPeso molecular:837.92SA-VA
SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.Fórmula:C50H53ClF3N11O7SPureza:98%Forma y color:SolidPeso molecular:1044.54FGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].
Fórmula:C26H27N4O6PPureza:98%Forma y color:SolidPeso molecular:522.49DSPE-PEG2000-GE11
DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.Forma y color:Odour SolidMP-RM-1
MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.Forma y color:Odour LiquidVEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Fórmula:C29H27N9OPureza:98%Forma y color:SolidPeso molecular:517.58AZ14240475
AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.Fórmula:C23H15ClF2N6O2Forma y color:SolidPeso molecular:480.854NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Fórmula:C43H51N11O6Forma y color:SolidPeso molecular:817.94Vulinacimab
CAS:Vulinacimab (HLX-06) is a mAb targeting VEGFR-2, used in cancer research, vital for tumor angiogenesis and endothelial cell functions.Forma y color:LiquidPROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97PROTAC EGFR degrader 8
CAS:PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.Fórmula:C40H46ClN11O5Pureza:98%Forma y color:SolidPeso molecular:796.32IOX2-NH2-Methyl
IOX2-NH2-Methyl is a modified form of IOX2. IOX2 is a specific inhibitor of PHD2 (prolyl-hydroxylase-2), capable of upregulating HIF-1α expression and suppressing ROS production. IOX2-NH2-Methyl is employed in investigations of platelet and thrombus formation.Fórmula:C20H19N3O5Pureza:97.64% - 99.31%Forma y color:SolidPeso molecular:381.39SJ1008030
CAS:SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.
Fórmula:C42H43N13O7SForma y color:SolidPeso molecular:873.94DSPE-PEG5000-A7R
DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Forma y color:Odour SolidEGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Fórmula:C26H20ClFN4OSForma y color:SolidPeso molecular:490.98PROTAC EGFR degrader 6
CAS:PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.Fórmula:C49H57FN12O5Forma y color:SolidPeso molecular:913.05Caffeic acid-pYEEIE
CAS:Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).
Fórmula:C39H50N5O19PPureza:98%Forma y color:SolidPeso molecular:923.82TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Forma y color:Odour SolidIbrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39hCA/VEGFR-2-IN-3
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.Fórmula:C24H28N6O6SPureza:98%Forma y color:SolidPeso molecular:528.58VEGFR-2-IN-66
VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.Forma y color:Odour SolidBRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Fórmula:C23H23ClFN7O2Forma y color:SolidPeso molecular:483.93JBJ-09-063 TFA
JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.Fórmula:C33H30F4N4O5SForma y color:SolidPeso molecular:670.67EGFR/HER2/DHFR-IN-2
EGFR/HER2/DHFR-IN-2 (Compound 4b) serves as an inhibitor for EGFR, HER2, and DHFR, with IC50 values of 0.248, 0.156, and 0.138 μM, respectively.
Pureza:98%Forma y color:Odour SolidFLT3-IN-23
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effectsForma y color:Odour SolidSNIPER(ABL)-013
SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 ofFórmula:C42H52F3N7O8Pureza:98%Forma y color:SolidPeso molecular:839.9
